FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W171808537> ?p ?o ?g. }

• W171808537 abstract "Type 2 diabetes is still rapidly on the rise today, affecting 10.5% of individuals in the United States between the ages 45 to 64 and 18.4% of those between the ages of 65 to 74. In the past two decades, type 2 diabetes has doubled in all age groups. Many adults with type 2 diabetes experience difficulty managing their blood sugars, which can result in a range of further complications. One of the newest treatment options on the market today is a glucagon-like peptide-1 (GLP-1) receptor agonist, Bydureon. Similar to Byetta, Bydureon has a main ingredient of exenatide. It offers once a week dosing as opposed to twice-a-day, which may be more appealing to patients. The purpose of this study was to examine the efficacy of a newly FDA released medication, Bydureon, once weekly dosage in adults with type 2 diabetes. A descriptive, comparative, retrospective study of 35 patients evaluated efficacy by examining Hgb A1C and body mass index in adults with type 2 diabetes at baseline and 3 months after Bydureon was prescribed. Data were collected by a chart review of records in a primary care practice. Results demonstrated a statistically significant difference between baseline to 3 month means in both Hgb A1C (t (34)= -3.05, p=.0044) and BMI (t (34) = -2.86, p = .0072) for patients using Bydureon. Health care providers need to individualize the patients’ plans of care to address multifactorial areas of their diabetes care and provide them with an opportunity to successfully meet their goals. Practitioners must be knowledgeable about the treatment options available, including the newer GLP-1 receptor agonist, Bydureon and its efficacy for adults with type 2 diabetes. Chapter One: Introduction Diabetes mellitus, more commonly referred to as diabetes, is a group of clinically heterogeneous metabolic disorders that are commonly characterized by glucose intolerance resulting from a defect in either the action and/or or secretion of insulin (Jones, Brashers, & Huether, 2010). It is estimated that some 25.8 million people of all ages in the United States (U.S.) have diabetes, approximately 8.3 percent of the total population (National Diabetes Information Clearinghouse [NDIC], 2011). Of these 25.8 million, only 18.8 million people are diagnosed. Diabetes is the seventh leading cause of death in the U.S. and one of the major causes of heart disease, stroke, renal failure, non-traumatic lower-limb amputations, and blindness. It is estimated that by 2030, the estimated worldwide population with diabetes will increase by 60 percent over the 2000 numbers (American Diabetes Association [ADA], 2012). This increase is due to the general population aging, as well as the eating and physical activity habits in the world, with a parallel increase in obesity (Van Dijk, et al., 2011). Although there is no cure for diabetes, there are a variety of clinical management strategies that can avoid or minimize complications, increase the survival rates, and improve quality of life for the individual with diabetes (American Diabetes Association [ADA], 2012). These strategies include patient education on management and monitoring of blood glucose levels, and maintaining blood glucose within the normal range. A number of antidiabetic medications have been developed to help individuals with type 2 diabetes achieve blood glucose levels. The most recent of these medications are the incretin mimetics including exenatide. Byetta, a twice daily subcutaneous dosage of exenatide was released by the FDA in April of" @default.
• W171808537 created "2016-06-24" @default.
• W171808537 creator A5053283625 @default.
• W171808537 date "2014-01-01" @default.
• W171808537 modified "2023-09-27" @default.
• W171808537 title "Efficacy of Bydureon in Adults with Type 2 Diabetes" @default.
• W171808537 cites W2038305120 @default.
• W171808537 cites W2043900831 @default.
• W171808537 cites W2057002261 @default.
• W171808537 cites W2072691447 @default.
• W171808537 cites W2103132883 @default.
• W171808537 cites W2107949845 @default.
• W171808537 cites W2129934471 @default.
• W171808537 cites W2146901298 @default.
• W171808537 cites W2156472431 @default.
• W171808537 cites W2158216255 @default.
• W171808537 cites W2159561462 @default.
• W171808537 cites W2327349465 @default.
• W171808537 cites W2520432709 @default.
• W171808537 hasPublicationYear "2014" @default.
• W171808537 type Work @default.
• W171808537 sameAs 171808537 @default.
• W171808537 citedByCount "0" @default.
• W171808537 crossrefType "journal-article" @default.
• W171808537 hasAuthorship W171808537A5053283625 @default.
• W171808537 hasConcept C126322002 @default.
• W171808537 hasConcept C134018914 @default.
• W171808537 hasConcept C187212893 @default.
• W171808537 hasConcept C2777180221 @default.
• W171808537 hasConcept C2777288759 @default.
• W171808537 hasConcept C2780221984 @default.
• W171808537 hasConcept C2780533449 @default.
• W171808537 hasConcept C2780668416 @default.
• W171808537 hasConcept C512399662 @default.
• W171808537 hasConcept C555293320 @default.
• W171808537 hasConcept C71924100 @default.
• W171808537 hasConceptScore W171808537C126322002 @default.
• W171808537 hasConceptScore W171808537C134018914 @default.
• W171808537 hasConceptScore W171808537C187212893 @default.
• W171808537 hasConceptScore W171808537C2777180221 @default.
• W171808537 hasConceptScore W171808537C2777288759 @default.
• W171808537 hasConceptScore W171808537C2780221984 @default.
• W171808537 hasConceptScore W171808537C2780533449 @default.
• W171808537 hasConceptScore W171808537C2780668416 @default.
• W171808537 hasConceptScore W171808537C512399662 @default.
• W171808537 hasConceptScore W171808537C555293320 @default.
• W171808537 hasConceptScore W171808537C71924100 @default.
• W171808537 hasLocation W1718085371 @default.
• W171808537 hasOpenAccess W171808537 @default.
• W171808537 hasPrimaryLocation W1718085371 @default.
• W171808537 hasRelatedWork W1964699583 @default.
• W171808537 hasRelatedWork W2071656555 @default.
• W171808537 hasRelatedWork W2098580078 @default.
• W171808537 hasRelatedWork W2118158628 @default.
• W171808537 hasRelatedWork W2139122489 @default.
• W171808537 hasRelatedWork W2406839919 @default.
• W171808537 hasRelatedWork W2500838529 @default.
• W171808537 hasRelatedWork W2531402696 @default.
• W171808537 hasRelatedWork W2791331980 @default.
• W171808537 hasRelatedWork W2916458129 @default.
• W171808537 hasRelatedWork W2946367335 @default.
• W171808537 hasRelatedWork W2992632965 @default.
• W171808537 hasRelatedWork W2996771477 @default.
• W171808537 hasRelatedWork W3000718093 @default.
• W171808537 hasRelatedWork W3017265669 @default.
• W171808537 hasRelatedWork W3128015534 @default.
• W171808537 hasRelatedWork W3207130184 @default.
• W171808537 hasRelatedWork W768726324 @default.
• W171808537 hasRelatedWork W2598939467 @default.
• W171808537 hasRelatedWork W3121906585 @default.
• W171808537 isParatext "false" @default.
• W171808537 isRetracted "false" @default.
• W171808537 magId "171808537" @default.
• W171808537 workType "article" @default.